Omeros Corporation OMER

The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

Omeros (OMER) stock is reacting to a clear shift in its financial story after the company reported second quarter 2026 results that moved from a prior net loss to positive net income. See our latest analysis for Omeros. The latest move to a closing share price of $17.35 comes after a sharp re-rating, with a 30-day share price return of 65.24% and a 1-year total shareholder return of 321.12%. This suggests momentum has accelerated following Omeros' earnings and buyback updates. If you are...

Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications.

Moby summary of Omeros Corporation's Q2 2026 earnings call

Gross revenues from YARTEMLEA reached $32.2 million in the quarter, nearly triple the $11.1 million recorded in the first quarter.

SEATTLE, August 12, 2026--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include:

SEATTLE, August 10, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results.

Starting October 1, hospitals can receive up to about $287,000 more from Medicare for each qualifying patient for Yartemlea, Omeros said.

SEATTLE, August 03, 2026--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) will re